⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544133 | 1.00 | — | — | |
| SCHEMBL3551986 | 1.00 | — | — | |
| SCHEMBL183673 | 1.00 | — | — | |
| SCHEMBL3542055 | 1.00 | — | — | |
| SCHEMBL3543735 | 1.00 | — | — | |
| Methane SCHEMBL18695290 | 0.97 | — | — | |
| SCHEMBL5084611 | 0.97 | — | — | |
| SCHEMBL21056142 | 0.97 | — | — | |
| SCHEMBL3951830 | 0.91 | ALDH1A1 (0.44) | — | |
| SCHEMBL1155 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088869-A | 3CL protease inhibitor and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| WO-2022203466-A1 | NOVEL PHENYLAMINOPYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY AGAINST LRRK2 AND USE THEREOF | 주식회사 스탠다임 | 2022-09-29 | — | — | WO | claimed |
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | claimed |
| CN-118344424-A | Compositions and methods for targeting CNS disorders | 萨奇治疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118344423-A | Compositions and methods for targeting CNS disorders | 萨奇治疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118339152-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118307623-A | Steroid compound, application thereof and pharmaceutical composition containing steroid compound | 北京华睿鼎信科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118302426-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-111936136-B | Novel imidazopyrimidine compounds and uses thereof | 儿童医学中心公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113993859-B | Heterocyclic compounds, methods of making and methods of using the same | 益方生物科技(上海)股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| EP-0559860-B1 | HALOVINYL-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1996-02-14 | — | — | EP | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |
| US-5364556-A | Halovinyl-derivatives | HOFFMANN-LA ROCHE INC. (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0559860-A1 | HALOVINYL-DERIVATIVES. | HOFFMANN LA ROCHE (CH) | 1993-09-15 | — | — | EP | disclosed |
| WO-1993007234-A1 | HALOVINYL-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-15 | — | — | WO | disclosed |
| US-4388311-A | 4,4,17A-TRIMETHYLANDROSTA-2,5-DIENE DERIVATIVES | G. D. SEARLE & CO. (US) | 1983-06-14 | — | — | US | disclosed |